27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Between April 30, 2020, and May 9, 2022, we randomly allocated 204 participants (109 [53%] women and 95 [47%] men) to the intervention group and 98 (60 [61%] women and 38 [39%] men) to the control group. 218 (72%) participants at 6 months and 178 (59%) at 12 months provided cost data. 2 key findings →
Design: RCT Participants: 302 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The trial occurred during the COVID-19 pandemic. 5 key findings →
Design: randomized controlled trial Participants: 106 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Overall, 7124 participants representative of Medicare beneficiaries 65 years or older were included. 5 key findings →
Design: cross-sectional Participants: 7,124 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Despite the growth in Medicare managed care enrollment, only 9 papers report the costs of care for individuals with ADRD within these plans, and only 1 study reports data less than 10 years old. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Our sample included 1001 participating and 3873 matched control SNFs. 5 key findings →
Design: cohort study Participants: 1,001 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Hospice enrollment correlates with reduced Medicare expenditures among younger decedents with cancer but increased expenditures among decedents without cancer and those older than 84 years of age. 2 key findings →
Design: retrospective cohort Participants: 245 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our results demonstrate delirium is a significant marker of mortality among seniors in the ED, and mortality risk is most salient in the first 3 months following an ED visit. 5 key findings →
Design: cohort study Participants: 26 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Due to valued informal care, costs of care for community-living patients with moderate dementia are significantly higher than for patients with mild dementia. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Dual-eligible older persons are at greater risk for decline in function and cognition after an ICU hospitalization than their more advantaged counterparts. 2 key findings →
Design: cohort study Participants: 641 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Using a nationally representative survey of older Americans with in-home cognitive testing, researchers estimated that dementia cost the US between $157 billion and $215 billion in 2010, depending on how unpaid family caregiving time is valued. 4 key findings →
Design: cohort Participants: 856 Evidence: high
Full summary, score breakdown and related studies → Original source
This study followed a national sample of Medicare beneficiaries who died and compared total health and long-term care spending in their final five years of life. 4 key findings →
Design: cohort Participants: 1,702 Evidence: high
Full summary, score breakdown and related studies → Original source
These findings indicate that AWV recipients had a timelier first MCI diagnosis than those who did not receive an AWV, but first ADRD diagnosis differed little. 5 key findings →
Design: cohort Participants: 549,516 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This cost-consequence analysis reveals economic benefits of treatment of moderate to severe AD with donepezil. 1 key finding →
Participants: 144 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Physical exercise and cognitive and social enrichment activities can enhance cognitive function in patients with chronic stroke, but their cost-effectiveness compared with a balance and tone program is uncertain. 5 key findings →
Participants: 120 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Among older Medicare beneficiaries, incident AF is common and has remained relatively stable for more than a decade. 3 key findings →
Design: cohort study Participants: 433,123 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Preventable hospital readmissions have been recognized as indicators of hospital quality, a source of increased healthcare expenditures, and a burden for patients, families, and caregivers. 2 key findings →
Design: cohort study Participants: 5,133 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Type 2 diabetes is associated with cognitive dysfunction and structural brain changes. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Collaborative dementia care programs are effective in addressing the needs of patients with dementia and their caregivers. 3 key findings →
Participants: 780 Evidence: high
Full summary, score breakdown and related studies → Original source
There were no differences in measures of effectiveness between initiation of active treatments or placebo (which represented watchful waiting) but the placebo group had significantly lower health care costs. 3 key findings →
Design: clinical trial Participants: 421 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The sample included 47 100 Medicare beneficiaries (25 900 women [54.9%]; mean [SD] age, 72.2 [11.4] years). 5 key findings →
Design: cohort study Participants: 47 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Behavioral prevention strategies can help maintain high levels of cognition and functional integrity, and can reduce the social, medical, and economic burden associated with cognitive aging and age-associated neurodegenerative diseases. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
This review found significant variation among the cost estimates and methodological quality. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
There is need for clearer articulation of the likely mechanisms by which advance care planning can lead to reduced care costs or improved cost-effectiveness, particularly for people who retain capacity. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Older adults at the end of life receive a high number of hours of help at the end of life, many from more than one caregiver, which may shape hospice access. 3 key findings →
Design: cohort study Participants: 1,868 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Between Jan 1, 2000, and Dec 31, 2016, of 63 038 019 individuals who were aged 65 years or older during the study period, we identified 1·0 million cases of Parkinson's disease and 3·4 million cases of Alzheimer's disease and related dementias based on primary and secondary diagnosis billing codes. 1 key finding →
Design: cohort study Participants: 19 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →